Since its launch in 2020, HercepTest™ mAb pharmDx (Dako Omnis) has participated in every bi-annual breast cancer assessment module that NordiQC has conducted. This external quality assessment scheme has repeatedly shown that HER2 assessments can be confidently performed on Dako Omnis with the HercepTest™ mAb pharmDx assay. In each assessment run, since module B30 (2020), HercepTest™ GE001 for Dako Omnis has provided the highest pass rate of 100% sufficient results when using vendor recommended protocol.
Nordic Immunohistochemical Quality Control (NordiQC) is an accredited international proficiency program for immunohistochemistry (IHC). More than 400 pathology laboratories are registered in the breast module and twice a year these laboratories participate in the program. IHC staining for HER2 is a standard in NordiQC’s breast module, where HercepTest™ mAb pharmDx (Dako Omnis) is being used by more and more laboratories.
Do you have questions? Would you like to learn more? Contact us and we will follow up with you.
For in vitro diagnostic (IVD) use.
Disclaimer: Please note that HercepTest™ mAb pharmDx (Dako Omnis) is not available in all countries. Contact us to hear about availability in your country.
D0036789_01